Markets

Delayed-release IPO: PLx Pharma postpones $68 million offering

A generic image of a dollar in front of a graph
Credit: Shutterstock photo

PLx Pharma, which is commercializing a delayed-release aspirin based on its proprietary lipid coating, postponed its IPO on Thursday. It had filed to raise $68 million by offering 3.8 million shares at a price range of $17 to $19. The IPO was delayed due to market conditions.

The Houston, TX-based company was founded in 2002. It had planned to list on the Nasdaq under the symbol PLXP. Raymond James and Maxim Group LLC were set to be the joint bookrunners on the deal.

The article Delayed-release IPO: PLx Pharma postpones $68 million offering originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PLXP

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More